Molecular analysis of cell-free DNA (cfDNA) that circulates in plasma and other body fluids
represents a “liquid biopsy” approach for non-invasive cancer screening or monitoring. The …

Qualitative and quantitative analysis of circulating cell-free DNA (cfDNA) is an emerging non-
invasive blood biomarker utilized to assess tumor progression and to evaluate prognosis …

Simple Summary Liquid biopsies provide a non-invasive means to diagnose and profile
tumors when tissue is not available. Sequence-based analysis of cell-free DNA (cfDNA) is …

Precision oncology is predicated upon the ability to detect specific actionable genomic
alterations and to monitor their adaptive evolution during treatment to counter resistance …

Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …

Circulating cell-free DNA (cfDNA) has received increasing interest as an apparent
breakthrough approach in diagnostics, personalized medicine, and tumor biology. However …

The increasing knowledge of the molecular pathogenesis of cancer and the rapid
development of new molecular techniques are promoting the study of early molecular …

Recently, many genome‐wide profiling studies provided insights into the molecular make‐
up of major cancer types. The deeper understanding of these genetic alterations and their …

Tumor-specific, circulating cell-free DNA (cfDNA) in liquid biopsy test is a novel promising
biomarker in the advancement of cancer management, including early diagnosis, screening …

Cell-free circulating DNA (cfDNA) in plasma has gained global interest as a diagnostic
material for noninvasive prenatal testing and cancer diagnosis, or the so-called “liquid …